Gate Bioscience Raises $60M in Series A Financing

▤ Summary

The company intends to use the funds to expand operations and its development efforts. Led by Jordi Mata-Fink, CEO, Gate Bioscience is a preclinical biotech company creating a new class of medicines called Molecular Gates. Its therapeutics are small molecules that aim to cure diseases by selectively eliminating harmful extracellular proteins at their origin: inside the cell. Every extracellular protein—of which there are more than 4,000—must pass through a single channel in the cell before it can be secreted into the body. With nowhere to go, the protein is redirected to be degraded by the cell’s natural cleanup mechanism instead of being secreted.

▦ Linked Companies